- Company
- Pharmaceuticals produced an average of 58 drugs 2018
- by Chon, Seung-Hyun Dec 30, 2019 06:19am
- Last year, Korean pharmaceutical companies produced 58 finished drugs on average. The amount produced per item was only &8361;900 million. Among the three in 3 pharmaceutical companies, the proportion of small-scale pharmaceuticals are high, with the annual output of less than &8361;1 billion. According to the '2019 Statistical Yearbook of
- Company
- Domestic sales of Nesina & Nesina act from next year by Jeil
- by Jung, Hye-Jin Dec 30, 2019 06:19am
- Takeda's sales of Nesina and Nessina act, diabetes treatments, will be back to Jeil Pharmaceutical Co.,Ltd in eight months. According to the distribution industry on the 26th, Jeil Pharmaceutical Co.,Ltd will be in charge of sales of Takeda's DPP-4 diabetes treatment Nesina and Nesina act from January 1 next year. Takeda carried out co
- Company
- Boryeong’s copyright of anti-cancer drug,commercial value↑
- by An, Kyung-Jin Dec 27, 2019 06:28am
- The anti-cancer drug 'Zepsyre', which is owned by Boryeong in Korea, has entered the early stage of commercialization. PharmaMar, the original developer, is expected to secure the first FDA indication for small cell lung cancer by August next year. The company also won a large contract worth up to &8361;640 billion to surpass the US copyrigh
- Company
- Discontinued sales of Champix generics
- by Kim, Min-Gun Dec 27, 2019 06:27am
- Pfizer's Champix (Varenicline) salt-changing patent disputes have resulted in the loss of more than 20 domestic pharmaceutical companies, which has resulted in the suspension and recovery of generic drugs. According to the industry on the 24th, Hutecs Korea, C-tri, Danajen announced that they will be discontinued due to the result of a mat
- Policy
- 'Brakes' on reimbursed drug’s listing process
- by Lee, Hye-Kyung Dec 27, 2019 06:27am
- This year, the insurance authorities were able to reorganize their drug price system to the organization of the person in charge of drug prices. Last year, The NHIS chairman Yong-ik Kim, who designed Moon Jae-in Care, was very active, and this year, there have been a number of institutional improvements that have been carried out by sta
- InterView
- Restriction on high dose of Xeljanz
- by Nho, Byung Chul Dec 26, 2019 10:15am
- Recently, the US FDA and the European Medicines Agency (EMA) have restricted the prescription of high doses of Pfizer JAK inhibitor Xeljanz (Tofacitinib citrate). The U.S. FDA changed its permits from primary to secondary for ulcerative colitis, one of the indications for Xeljanz, in July. The EMA has a high risk of thrombotic ulcerative
- Policy
- Severe atopic drug Dupixent listed, first benefit from RSA
- by Kim, Jung-Ju Dec 26, 2019 06:34am
- Sanofi Aventis' treatment for severe atopic dermatitis, Dupixent PFS 300mg (Dupilumab), will be listed next month after all of its reimbursment hurdles. Although it was not an anticancer drug or a rare disease treatment agent, there was a difficulty in expanding the RSA, but the government and the health authorities were able to follow thi
- Policy
- Unpaid medical benefits “fully solved next month”
- by Kim, Jung-Ju Dec 26, 2019 06:31am
- The government reflected the unpaid medical benefits in the budget of &8361;100 billion in next year's budget. Most of this year's unpaid payments have been resolved, and the unpaid payments of nursing institutions, which appeared at the beginning & the end of the year, are being resolved somewhat. However, dues are reflected in next year's
- Product
- Oral treatment by Sanofi has the highest number of defects
- by Kim JiEun Dec 26, 2019 06:30am
- Ten defects were found in the same product of the same company a year The Seoul Pharmaceutical Society (Chairman Dong-ju Han), the pharmacy committee (Vice chairman Yong-seok Choi, Head Commissioner Woo-young Chang, Soo-hyun Byun, and Tae-seok Kang), and the Pharmacist Guidance Committee (Chairman Kyung-Jin Jeon and Soo-Yul Lim) announced
- Company
- Kyowa Kirin Korea appoints Lee Sang Heon as next CEO
- by Eo, Yun-Ho Dec 26, 2019 06:30am
- On Dec. 20, Kyowa Kirin Korea announced the promotion of current Chief Operating Officer Lee Sang Heon (54) as a Chief Executive Officer from Jan. 2, 2020. Graduated from Seoul High School and Yonsei University majoring in bioengineering, soon-to-be CEO Lee Sang Heon had experience in marketing and business alliance in Boryung Pharmaceu
